コレステロール応答性肝臓tRNA由来小RNAによるコレステロールホメオスタシスおよびアテローム性動脈硬化発生の調節
Xiuchun Li1, Rebecca Hernandez1, Xudong Zhang2,3
1Division of Biomedical Sciences, School of Medicine, University of California, Riverside, CA, USA.
Nature communications
|December 15, 2025
まとめ
トランスファーRNA由来小RNA(tsRNA)はコレステロールを調節する。本研究では、肝臓におけるtsRNA-Glu-CTCを同定し、高コレステロール血症、肝性脂肪症、アテローム性動脈硬化におけるその役割を示し、心血管代謝疾患の新たな治療標的を提供する。
科学分野:
- 分子生物学
- 心血管生物学
- RNA生物学
背景:
- トランスファーRNA由来小RNA(tsRNA)は、その生物学的役割がますます認識されています。
- 脂質代謝および心血管疾患におけるtsRNAの特定の機能はよく理解されていません。
研究 の 目的:
- tsRNAが脂質代謝および心血管疾患において果たす役割を調査すること。
- コレステロールホメオスタシスに関与する新規tsRNAを同定および特徴づけること。
主な方法:
- tsRNA同定のためのPANDORA-seq。
- 高コレステロール血症、肝性脂肪症、アテローム性動脈硬化のinvivoマウスモデル。
- RNA修飾分析のためのMLC-seq。
- 遺伝子発現評価のための分子アッセイ。
主要な成果:
- tsRNA-Glu-CTCはマウス肝臓で最も豊富なtsRNAとして同定され、コレステロール応答性でした。
- tsRNA-Glu-CTCの過剰発現は、高コレステロール血症および肝性脂肪症につながりました。
- tsRNA-Glu-CTCのノックダウンは、食事誘発性高コレステロール血症およびアテローム性動脈硬化に対して保護的でした。
- tsRNA-Glu-CTCは、E-boxモチーフを介してSREBP2転写を直接調節します。
- 部位特異的RNA修飾は、コレステロールホメオスタシスに対するtsRNA-Glu-CTCの調節効力を高めます。
結論:
- 肝臓に豊富に存在するtsRNAであるtsRNA-Glu-CTCは、脂質代謝の調節において重要な役割を果たします。
- tsRNA-Glu-CTCは、高コレステロール血症およびアテローム性動脈硬化の主要なメディエーターです。
- このtsRNAとその修飾は、心血管代謝疾患の潜在的な治療標的を表します。
関連する概念動画
Cholesterol: Significance and Regulation
1.2K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
1.2K
Regulation of Nuclear Protein Sorting
3.2K
Nuclear protein sorting regulates nucleus composition and gene expression, crucial for determining the fate of a eukaryotic cell. Hence, the entry and exit of molecules across the nuclear envelope is a tightly controlled process. Nuclear protein sorting can be inhibited by one of the following ways: 1) masking cargo signal sequences, 2) modifying the nuclear receptor's affinity for cargo, 3) controlling the nuclear pore size, 4) retaining the cargo during its transit to the cytosol or the...
3.2K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
Translational Regulation
507
Translational regulation in prokaryotes ensures efficient protein synthesis by controlling ribosome access to mRNA. This regulation is mediated by secondary RNA structures, including translational riboswitches, RNA thermometers, and small RNAs (sRNAs), which respond to intracellular and environmental signals to modulate gene expression.Translational RiboswitchesRiboswitches in the leader region of mRNAs can regulate translation by altering the accessibility of the Shine-Dalgarno (SD) sequence,...
507
Experimental RNAi
7.2K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
7.2K
Atherosclerosis III: Management
293
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
293


